Appearance
Liquid biopsies.
Literature Information
| DOI | 10.1002/gcc.22695 |
|---|---|
| PMID | 30382599 |
| Journal | Genes, chromosomes & cancer |
| Impact Factor | 2.8 |
| JCR Quartile | Q2 |
| Publication Year | 2019 |
| Times Cited | 77 |
| Keywords | circulating tumor DNA, circulating tumor cells, liquid biopsy |
| Literature Type | Journal Article, Research Support, Non-U.S. Gov't, Review |
| ISSN | 1045-2257 |
| Pages | 219-232 |
| Issue | 58(4) |
| Authors | Evi Lianidou, Klaus Pantel |
TL;DR
This review highlights the transformative potential of liquid biopsy in cancer treatment, emphasizing its minimally invasive nature and ability to provide real-time molecular profiling through the analysis of circulating tumor cells, circulating tumor DNA, and other tumor-derived materials. By identifying predictive biomarkers in peripheral blood, liquid biopsy could significantly enhance therapeutic management and monitoring of cancer patients.
Search for more papers on MaltSci.com
circulating tumor DNA · circulating tumor cells · liquid biopsy
Abstract
Liquid biopsy is based on minimally invasive blood tests and has a high potential to significantly change the therapeutic strategy in cancer patients, providing an extremely powerful and reliable noninvasive clinical tool for the individual molecular profiling of patients in real time. Liquid biopsy approaches include the analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating miRNAs, and tumor-derived extracellular vesicles (EVs) that are shed from primary tumors and their metastatic sites into peripheral blood. The major advantage of liquid biopsy analysis is that it is minimally invasive, and can be serially repeated, thus allowing extracting information from the tumor in real time. Moreover, the identification of predictive biomarkers in peripheral blood that can monitor response to therapy in real time holds a very strong potential for novel approaches in the therapeutic management of cancer patients. In this review, we summarize recent knowledge on CTCs and ctDNA and discuss future trends in the field.
MaltSci.com AI Research Service
Intelligent ReadingAnswer any question about the paper and explain complex charts and formulas
Locate StatementsFind traces of a specific claim within the paper
Add to KBasePerform data extraction, report drafting, and advanced knowledge mining
Primary Questions Addressed
- What are the specific advantages of using circulating tumor cells (CTCs) compared to circulating tumor DNA (ctDNA) in liquid biopsy applications?
- How do liquid biopsies enhance the monitoring of treatment responses in cancer patients over traditional biopsy methods?
- What are the potential limitations or challenges associated with the implementation of liquid biopsy technologies in clinical practice?
- In what ways can the analysis of circulating miRNAs and tumor-derived extracellular vesicles (EVs) contribute to the understanding of cancer progression and treatment efficacy?
- How might the integration of artificial intelligence and machine learning improve the interpretation of data obtained from liquid biopsies?
Key Findings
1. Research Background and Objectives
Liquid biopsy represents a groundbreaking advancement in oncology, offering a minimally invasive alternative to traditional tissue biopsies for cancer diagnosis and monitoring. The primary aim of this research is to explore the capabilities of liquid biopsy in providing real-time molecular profiling of cancer patients. This approach utilizes various components found in peripheral blood, such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating microRNAs (miRNAs), and tumor-derived extracellular vesicles (EVs). The goal is to enhance therapeutic strategies by identifying predictive biomarkers that can inform treatment decisions and monitor patient response effectively.
2. Main Methods and Findings
The review comprehensively analyzes the methodologies involved in liquid biopsy, emphasizing the extraction and analysis of CTCs and ctDNA. The findings indicate that liquid biopsies enable the continuous monitoring of tumor dynamics, including tumor evolution and treatment response, by capturing real-time data from the bloodstream. By examining these components, researchers can identify genetic mutations and other biomolecular markers associated with specific cancers. The review highlights recent advancements in the sensitivity and specificity of detection technologies, which have improved the reliability of liquid biopsy results.
3. Key Conclusions
The study concludes that liquid biopsy serves as a powerful, non-invasive clinical tool that can significantly alter the therapeutic landscape for cancer patients. The ability to conduct serial testing allows for the monitoring of disease progression and treatment efficacy over time. Furthermore, the identification of predictive biomarkers through liquid biopsy can facilitate personalized treatment plans, thereby optimizing patient outcomes. The review advocates for the increased integration of liquid biopsy into clinical practice and emphasizes the need for continued research to fully realize its potential.
4. Research Significance and Impact
The significance of this research lies in its potential to transform cancer management practices. Liquid biopsy not only reduces the need for invasive procedures but also provides a dynamic approach to understanding tumor behavior and treatment response. This technology stands to enhance patient care by allowing for timely adjustments in therapy based on real-time data. The implications extend beyond individual patient management to broader public health outcomes, as liquid biopsies could improve early detection and monitoring of various cancers, ultimately contributing to better survival rates. The review serves as a call to action for the oncology community to embrace liquid biopsy as a standard diagnostic tool, fostering further innovations in cancer treatment and patient management strategies.
Literatures Citing This Work
- Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer. - Corinna Keup;Markus Storbeck;Siegfried Hauch;Peter Hahn;Markus Sprenger-Haussels;Mitra Tewes;Pawel Mach;Oliver Hoffmann;Rainer Kimmig;Sabine Kasimir-Bauer - Cancers (2019)
- Circulating Tumor Cell Detection in Lung Cancer: But to What End? - Véronique Hofman;Simon Heeke;Charles-Hugo Marquette;Marius Ilié;Paul Hofman - Cancers (2019)
- Nuclease-Assisted Minor Allele Enrichment Using Overlapping Probes-Assisted Amplification-Refractory Mutation System: An Approach for the Improvement of Amplification-Refractory Mutation System-Polymerase Chain Reaction Specificity in Liquid Biopsies. - Athina Markou;Elena Tzanikou;Ioannis Ladas;G Mike Makrigiorgos;Evi Lianidou - Analytical chemistry (2019)
- A hybridization chain reaction based assay for fluorometric determination of exosomes using magnetic nanoparticles and both aptamers and antibody as recognition elements. - Liangliang Shi;Li Ba;Ying Xiong;Gang Peng - Mikrochimica acta (2019)
- Novel Epigenetic Biomarkers in Pregnancy-Related Disorders and Cancers. - Valentina Karin-Kujundzic;Ida Marija Sola;Nina Predavec;Anamarija Potkonjak;Ema Somen;Pavao Mioc;Alan Serman;Semir Vranic;Ljiljana Serman - Cells (2019)
- Summer School in Flow Cytometry for Immunology: Report From a Successful ESCCA Experience. - Katherina Psarra;Genny Del Zotto;Alexandra Fleva;Areti Strati;Marianna Tzanoudaki;Silvia Della Bella - EJIFCC (2019)
- Extracellular Vesicles-Based Biomarkers Represent a Promising Liquid Biopsy in Endometrial Cancer. - Carolina Herrero;Alexandre de la Fuente;Carlos Casas-Arozamena;Victor Sebastian;Martin Prieto;Manuel Arruebo;Alicia Abalo;Eva Colás;Gema Moreno-Bueno;Antonio Gil-Moreno;Ana Vilar;Juan Cueva;Miguel Abal;Laura Muinelo-Romay - Cancers (2019)
- Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer. - Qian Chen;Zi-Han Zhang;Shu Wang;Jing-He Lang - OncoTargets and therapy (2019)
- Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer. - Carlos Casas-Arozamena;Eva Díaz;Cristian Pablo Moiola;Lorena Alonso-Alconada;Alba Ferreirós;Alicia Abalo;Carlos López Gil;Sara S Oltra;Javier de Santiago;Silvia Cabrera;Victoria Sampayo;Marta Bouso;Efigenia Arias;Juan Cueva;Eva Colas;Ana Vilar;Antonio Gil-Moreno;Miguel Abal;Gema Moreno-Bueno;Laura Muinelo-Romay - Journal of clinical medicine (2020)
- The Landscape of Targeted Therapies in TNBC. - Elena Vagia;Devalingam Mahalingam;Massimo Cristofanilli - Cancers (2020)
... (67 more literatures)
© 2025 MaltSci - We reshape scientific research with AI technology